Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Mabuterol Recombinant Mouse Monoclonal Antibody (4E2)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Mabuterol Antibody (MA566431) in SDS-PAGE
SDS-PAGE characterization of Mabuterol under reducing conditions. Lane M: Protein marker (kDa); Lane MAB: Purified Mabuterol Recombinant Monoclonal (Product # MA566431). Mabuterol showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-262.
产品信息
MA566431
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
4E2
抗原
Conjugate of MAB hapten and KLH.
偶联物
形式
Liquid
浓度
7.6 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Mabuterol is a biosimilar monoclonal antibody developed for therapeutic use, particularly in the treatment of cancer. The development of Mabuterol involves leveraging innovator formulation knowledge to create alternative formulations that are cost-effective and time-efficient. Located on chromosome 14, Mabuterol's gene structure includes variable regions that are crucial for its antigen-binding functionality. The biosimilar exhibits comparable efficacy, safety, and immunogenicity to its reference products, as demonstrated in prelicensing studies and postmarketing surveillance. The development strategy for Mabuterol considers patent expirations and aims to avoid infringement, ensuring a smooth pathway for market entry. This biosimilar is part of a broader strategy to enhance the accessibility of monoclonal antibody therapies in oncology.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
